Viral Vector Manufacturing Market Scope And Analysis

  • Report Code : TIPRE00038970
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Viral Vector Manufacturing Market Scope, Analysis, and Trends by 2030

Buy Now


Viral Vector Manufacturing Market Report Scope

Report Attribute Details
Market size in 2022 US$ 1.29 Billion
Market Size by 2030 US$ 5.00 Billion
Global CAGR (2022 - 2030) 18.4%
Historical Data 2020-2022
Forecast period 2022-2030
Segments Covered By Type
  • Adenoviral Vectors
  • Adeno-Associated Viral Vectors
  • Lentiviral Vectors
  • Retroviral Vectors
By Disease Indication
  • Cancer
  • Genetic Disorders
  • Infectious Disease
By Application
  • Therapeutics Development
  • Vaccine Development
  • CDMOs & CROs
By End User
  • Pharmaceutical and Biotechnology Companies
  • Research Institutes
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Charles River Laboratories
  • Merck KGaA
  • Biovian Oy
  • Global Life Sciences Solutions USA LLC
  • Lonza Group Ltd
  • Creative Biogene
  • VIVEbiotech SL
  • Genezen Laboratories Inc
  • GenScript Biotech Corporation
  • Competitive Landscape and Key Companies:

    Charles River Laboratories, Merck KGaA, Biovian Oy, Global Life Sciences Solutions USA LLC, Lonza Group Ltd, Creative Biogene, VIVEbiotech SL, Genezen Laboratories Inc, GenScript Biotech Corporation, and AGC Biologics are among the prominent players operating in the viral vector manufacturing market. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios.